Your browser is no longer supported. Please, upgrade your browser.
Kodiak Sciences Inc.
Index- P/E- EPS (ttm)-3.33 Insider Own0.40% Shs Outstand51.57M Perf Week-2.26%
Market Cap4.50B Forward P/E- EPS next Y-6.12 Insider Trans-19.37% Shs Float45.26M Perf Month-9.85%
Income-159.20M PEG- EPS next Q-1.06 Inst Own89.00% Short Float7.96% Perf Quarter-30.62%
Sales- P/S- EPS this Y-132.50% Inst Trans2.54% Short Ratio10.23 Perf Half Y-33.62%
Book/sh15.93 P/B5.26 EPS next Y-33.00% ROA-21.10% Target Price121.60 Perf Year76.54%
Cash/sh17.29 P/C4.85 EPS next 5Y12.40% ROE-28.00% 52W Range45.02 - 171.21 Perf YTD-42.93%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.03% Beta-
Dividend %- Quick Ratio26.60 Sales past 5Y- Gross Margin- 52W Low86.23% ATR4.20
Employees77 Current Ratio26.60 Sales Q/Q- Oper. Margin- RSI (14)42.37 Volatility5.65% 4.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-79.80% Profit Margin- Rel Volume0.83 Prev Close87.87
ShortableYes LT Debt/Eq0.00 EarningsMay 10 BMO Payout- Avg Volume352.40K Price83.84
Recom2.50 SMA20-6.81% SMA50-2.52% SMA200-26.40% Volume292,207 Change-4.59%
May-11-21Upgrade ROTH Capital Neutral → Buy $155 → $149
Mar-12-21Initiated Evercore ISI Outperform
Mar-01-21Downgrade Barclays Equal Weight → Underweight $52 → $90
Feb-17-21Downgrade ROTH Capital Buy → Neutral $133 → $155
Jan-25-21Downgrade BMO Capital Markets Outperform → Market Perform $145 → $148
Dec-17-20Initiated Berenberg Buy $156
Dec-16-20Initiated UBS Buy $170
Dec-11-20Initiated Citigroup Neutral $134
Nov-30-20Downgrade JP Morgan Overweight → Neutral $74 → $125
Nov-16-20Downgrade Morgan Stanley Overweight → Equal-Weight $80 → $125
Nov-13-20Downgrade Goldman Buy → Neutral $83 → $105
Mar-31-20Initiated BMO Capital Markets Outperform $74
Mar-03-20Initiated Goldman Buy $80
Feb-18-20Downgrade Barclays Overweight → Equal Weight $69
Feb-06-20Initiated SunTrust Buy
Jan-08-20Initiated ROTH Capital Buy $115
Jan-03-20Initiated Jefferies Buy $100
Dec-24-19Initiated JP Morgan Overweight $82
Oct-15-19Reiterated Chardan Capital Markets Buy $22.50 → $35
Feb-20-19Initiated Chardan Capital Markets Buy $22.50
Jul-29-21 07:00AM  
Jul-27-21 08:05PM  
Jul-23-21 07:33AM  
Jun-09-21 11:30AM  
May-20-21 07:00PM  
May-19-21 09:58AM  
May-18-21 02:00AM  
May-11-21 11:04AM  
May-10-21 12:30PM  
May-06-21 12:19PM  
May-04-21 12:00PM  
Apr-21-21 06:59PM  
Mar-02-21 04:12PM  
Mar-01-21 05:30AM  
Feb-16-21 06:07AM  
Feb-13-21 08:28AM  
Feb-09-21 04:50AM  
Feb-02-21 07:14AM  
Jan-05-21 08:02AM  
Dec-18-20 01:41AM  
Nov-27-20 03:02PM  
Nov-20-20 04:03PM  
Nov-17-20 09:02PM  
Nov-16-20 04:01PM  
Nov-12-20 04:12PM  
Nov-11-20 11:27PM  
Nov-10-20 11:44AM  
Nov-09-20 05:30AM  
Oct-26-20 07:53AM  
Oct-12-20 04:56PM  
Oct-05-20 09:02AM  
Sep-02-20 04:08PM  
Aug-10-20 05:30AM  
Jul-31-20 06:00AM  
Jul-16-20 04:38PM  
Jul-10-20 04:00PM  
Jul-07-20 08:38AM  
Jul-05-20 03:30PM  
Jun-12-20 10:20PM  
Jun-05-20 12:00PM  
May-29-20 01:38PM  
May-28-20 08:22AM  
May-26-20 11:02AM  
May-13-20 07:01AM  
May-11-20 04:13PM  
May-08-20 04:30PM  
Apr-07-20 11:35AM  
Apr-02-20 04:08PM  
Mar-24-20 04:23PM  
Mar-23-20 01:37PM  
Mar-18-20 02:29PM  
Mar-16-20 05:30AM  
Mar-03-20 12:08PM  
Feb-27-20 06:00AM  
Feb-21-20 03:14PM  
Feb-08-20 03:30PM  
Jan-14-20 03:56PM  
Jan-08-20 06:00AM  
Dec-27-19 02:19PM  
Dec-26-19 07:55AM  
Dec-25-19 11:30AM  
Dec-24-19 12:00PM  
Dec-22-19 01:21PM  
Dec-20-19 07:30AM  
Dec-19-19 04:01PM  
Dec-14-19 07:30AM  
Dec-06-19 04:15PM  
Dec-03-19 09:07PM  
Dec-02-19 05:00PM  
Nov-27-19 12:15PM  
Nov-12-19 07:20AM  
Nov-08-19 07:00AM  
Oct-11-19 07:58PM  
Oct-10-19 07:39PM  
Oct-07-19 06:00AM  
Oct-04-19 02:27PM  
Sep-15-19 06:08AM  
Sep-12-19 06:00AM  
Sep-06-19 06:00AM  
Sep-04-19 06:30PM  
Aug-23-19 11:36AM  
Aug-14-19 05:30AM  
Aug-08-19 06:00AM  
Jul-27-19 12:47PM  
Jul-24-19 07:00AM  
Jul-17-19 10:09AM  
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EHRLICH JASONSee RemarksJul 20Sale86.286,950599,62453,233Jul 22 04:37 PM
EHRLICH JASONSee RemarksJun 21Sale84.906,950590,08560,183Jun 23 05:38 PM
EHRLICH JASONSee RemarksJun 15Sale84.751,14797,20864,968Jun 15 07:06 PM
BORGESON JOHN A.See RemarksJun 15Sale84.751,03787,886167,990Jun 15 07:04 PM
EHRLICH JASONSee RemarksJun 15Sale80.901,454117,62467,133Jun 17 09:26 PM
BORGESON JOHN A.See RemarksJun 15Sale80.901,290104,361170,319Jun 17 09:24 PM
EHRLICH JASONSee RemarksMay 20Sale81.146,950563,92463,161May 24 04:59 PM
EHRLICH JASONSee RemarksMay 12Option Exercise10.217,26874,24070,111May 14 05:22 PM
EHRLICH JASONSee RemarksApr 20Option Exercise10.296,95071,51669,793Apr 22 04:59 PM
EHRLICH JASONSee RemarksApr 20Sale111.266,950773,24962,843Apr 22 04:59 PM
EHRLICH JASONSee RemarksMar 22Option Exercise10.296,95071,51669,793Mar 24 05:07 PM
EHRLICH JASONSee RemarksMar 22Sale131.506,950913,89462,843Mar 24 05:07 PM
BORGESON JOHN A.See RemarksMar 10Sale130.085,000650,415165,899Mar 12 05:02 PM
EHRLICH JASONSee RemarksMar 03Option Exercise10.2912,500128,62562,843Mar 05 05:44 PM
EHRLICH JASONSee RemarksFeb 22Option Exercise10.296,95071,51657,293Feb 24 04:44 PM
EHRLICH JASONSee RemarksFeb 22Sale125.816,950874,36750,343Feb 24 04:44 PM
EHRLICH JASONSee RemarksJan 20Option Exercise10.2926,950277,31677,293Jan 22 05:22 PM
EHRLICH JASONSee RemarksJan 20Sale162.7726,9504,386,77650,343Jan 22 05:22 PM
EHRLICH JASONSee RemarksDec 23Option Exercise10.297,50077,17550,343Dec 23 05:40 PM
EHRLICH JASONSee RemarksDec 21Option Exercise10.296,95071,51649,793Dec 23 05:40 PM
EHRLICH JASONSee RemarksDec 21Sale144.556,9501,004,61042,843Dec 23 05:40 PM
EHRLICH JASONSee RemarksNov 20Option Exercise10.296,95071,51649,793Nov 24 06:04 PM
EHRLICH JASONSee RemarksNov 20Sale138.796,950964,60142,843Nov 24 06:04 PM
EHRLICH JASONSee RemarksOct 27Option Exercise10.297,50077,17550,343Oct 29 04:49 PM
EHRLICH JASONSee RemarksOct 27Sale100.007,500750,00042,843Oct 29 04:49 PM
EHRLICH JASONSee RemarksOct 23Option Exercise10.297,50077,17550,343Oct 27 04:57 PM
EHRLICH JASONSee RemarksOct 23Sale86.257,500646,87542,843Oct 27 04:57 PM
EHRLICH JASONSee RemarksOct 20Option Exercise10.296,95071,51649,793Oct 22 04:56 PM
EHRLICH JASONSee RemarksOct 20Sale78.396,950544,81742,843Oct 22 04:56 PM
EHRLICH JASONSee RemarksOct 13Option Exercise10.295,00051,45047,843Oct 15 05:44 PM
EHRLICH JASONSee RemarksOct 13Sale75.005,000375,00042,843Oct 15 05:44 PM
EHRLICH JASONSee RemarksOct 09Sale71.282,200156,81942,843Oct 13 07:04 PM
BAKER BROS. ADVISORS LPDirectorSep 25Buy56.6548,1252,726,18211,324,937Sep 25 06:02 PM
BAKER BROS. ADVISORS LPDirectorSep 24Buy52.0236,0201,873,92411,280,001Sep 24 07:30 PM
BAKER BROS. ADVISORS LPDirectorSep 23Buy52.4392,0694,826,75611,246,368Sep 24 07:30 PM
BAKER BROS. ADVISORS LPDirectorSep 22Buy50.6774,9583,797,91111,160,400Sep 24 07:30 PM
EHRLICH JASONSee RemarksSep 21Option Exercise10.296,95071,51640,934Sep 23 06:15 PM
EHRLICH JASONSee RemarksSep 21Sale52.406,950364,18233,984Sep 23 06:15 PM
BAKER BROS. ADVISORS LPDirectorSep 08Buy47.34116,2955,505,93411,090,409Sep 08 05:58 PM
BAKER BROS. ADVISORS LPDirectorSep 04Buy46.7382,8013,869,47310,982,772Sep 08 05:58 PM
BAKER BROS. ADVISORS LPDirectorSep 03Buy47.97123,8835,942,90410,905,982Sep 08 05:58 PM
BAKER BROS. ADVISORS LPDirectorAug 21Buy48.63139,0446,762,05610,791,092Aug 21 05:19 PM
EHRLICH JASONSee RemarksAug 20Option Exercise10.296,95071,51640,934Aug 24 04:56 PM
BAKER BROS. ADVISORS LPDirectorAug 20Buy47.4060,5732,871,15610,662,260Aug 21 05:19 PM
EHRLICH JASONSee RemarksAug 20Sale47.116,950327,44433,984Aug 24 04:56 PM
BAKER BROS. ADVISORS LPDirectorAug 19Buy46.993,869181,79110,606,135Aug 21 05:19 PM